Clinical Trial Update: A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pegvisomant for growth hormone excess in McCune-Albright syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mccune-albright Syndrome
• Polyostotic Fibrous Dysplasia

Drugs mentioned

• Pegvisomant (pegvisomant)

Snippet

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) | Conditions: McCune Albright Syndrome, Polyostotic Fibrous Dysplasia | Phase 3 | Status: COMPLETED